Perfusion Medical, an emerging biopharmaceutical company developing a pipeline of life-saving, acute cardiovascular therapies to transform intensive care medicine, today announced that it has received a scholarship from the Virginia Biotechnology Research Partnership Authority to participate in the BIO International Convention, June 16-19, 2025, in Boston, MA.

“We are grateful for the support from Virginia Bio, and we are glad to contribute to Virginia’s life-science ecosystem with our technology, PM-208, which was discovered and developed at Virginia Commonwealth University,” said Perfusion’s Chief Executive Officer, Gerard Eldering. “We are excited to convene with industry leaders to discuss the progress of PM-208, which is designed to treat severe hypovolemic shock by increasing tissue perfusion and facilitating rapid transfer of oxygen into oxygen-starved tissues and organs.”

During BIO International, Perfusion’s Operations Lead, Liz Bloomfield, will conduct one-on-one meetings with registered investors and potential partners to discuss its lead candidate, PM-208, a novel IV therapeutic designed to rapidly re-establish blood flow through tissue capillaries, resolving ischemia and enhancing organ perfusion. PM-208 is designed to treat capillary compression due to ischemia – a major unsolved problem in hemorrhagic shock as well as other ischemic injuries, including acute kidney injury, cardiac bypass dysfunction, and ischemic reperfusion injury.

“Virginia Bio is proud to facilitate Perfusion Medical’s invitation to this year’s BIO International Convention, as the company provides a perfect example of the healthcare advances being developed in our state,” said John Newby, Chief Executive Officer of Virginia Bio. “Virginia Bio works to foster a life sciences ecosystem and is recognized nationally for its innovation, commercial success, and contributions to improved health for all. Notably, Perfusion’s potentially life-saving technology has received consistent support from the military, pointing to a major benefit to growing a life-science company in our state.”